Quantcast

Latest Amgen Inc. Stories

2009-09-08 08:31:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Nanomedicine http://www.reportlinker.com/p0131218/Nanomedicine.html This report analyzes the Global Market for Nanomedicine in Millions of US$ by the following Application Areas: Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials, and Others. Annual forecasts are provided for the period of 2006 through 2015. The report profiles 263 companies...

2009-09-02 11:00:00

NEW YORK, Sept. 2 /PRNewswire/ -- Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City. The fashion show recognizes people with moderate to severe plaque psoriasis who have not allowed the condition to inhibit their personal style. Winners of the Addressing Psoriasis(TM) contest are...

2009-08-13 17:37:00

THOUSAND OAKS, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) issued the following statement on the outcome of today's meeting with the U.S. Food and Drug Administration (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD) to review the potential use of Prolia(TM) (denosumab) for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate cancer or breast...

2009-08-13 06:52:00

THOUSAND OAKS, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer patients undergoing hormone ablation at a meeting with the U.S. Food and Drug Administration's (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). "There remains...

2293915ec0df6bff37a46f9afad9959b1
2009-08-12 14:52:34

Studies suggest that a first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments and could soon add a more expensive but easier option to the booming market, The Associated Press reported. Amgen Inc's genetically engineered denosumab only requires two shots a year and could be approved for sale this fall. Many osteoporosis patients stop taking other drugs due to side effects or frequent dosing. But doctors say denosumab's high cost may be a...

2009-08-11 09:05:00

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss. In both studies, published today in The New England Journal of...

2009-07-27 08:31:00

CHICAGO, July 27 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for AMGN, NOK, AET, MW, and TTM. Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/072709B (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: Amgen Inc. (Nasdaq: AMGN), Nokia Corp. (NYSE: NOK), Aetna Inc. (NYSE: AET), Men's Wearhouse Inc. (NYSE: MW), and Tata Motors Ltd....

2009-07-17 18:10:00

THOUSAND OAKS, Calif., July 17 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for the epidermal growth factor receptor (EGFr) class of antibodies, including Vectibix((R)) (panitumumab). This decision follows the FDA's December 2008 Oncologics Drugs Advisory Committee (ODAC) meeting where the clinical utility of the KRAS gene as a predictive biomarker in patients with...

2009-07-06 12:16:00

NEW YORK, July 6 /PRNewswire/ -- Amgen and Wyeth today announced the eight winners of the Addressing Psoriasis(TM) contest, which recognizes people with moderate to severe plaque psoriasis who have tried not to allow the condition to inhibit their personal style. The winners will help raise public awareness of the condition by walking the runway in the Addressing Psoriasis(TM) Fashion Show hosted by television host and fashion consultant, Tim Gunn ("Project Runway," and "Tim Gunn's Guide to...

2009-06-22 14:29:00

Advisory Committee to Review Denosumab Data THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has asked the company to participate in a meeting of the Reproductive Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. The RHDAC will review data supporting the Biologics License Application (BLA) for denosumab, a RANK Ligand inhibitor for which Amgen is seeking approval for prevention and...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related